Acquisitions And Other Transactions (Narrative) (Details) (USD $)	0 Months Ended	12 Months Ended			24 Months Ended		0 Months Ended	12 Months Ended		0 Months Ended
	Sep. 07, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2010	Mar. 26, 2009	Dec. 23, 2011 Pfizer Respiratory Delivery Platform [Member]	Dec. 31, 2009 Biocon Limited [Member]	Dec. 31, 2011 Other 2011 Acquisitions [Member]	Sep. 07, 2010 Maximum [Member]
Business Acquisition [Line Items]
Total purchase consideration		$ 165,000,000					$ 348,000,000
Purchase consideration paid		59,000,000	16,000,000		16,000,000		22,000,000
Assumed liabilities in acquired entity		51,000,000					4,000,000
Business acquisition, contingent consideration		376,100,000					322,000,000		54,000,000
IPR & D identified in acquisition	143,000,000	30,000,000					338,000,000
Fixed assets acquired in acquisition	622,781,000						8,000,000
Fixed assets acquired in acquisition	16,211,000	5,000,000
Goodwill	207,390,000						1,000,000
Percentage of voting rights held in less than wholly owned subsidiary	100.00%					76.00%
Purchase price for acquisition of assets and liabilities for Bionic Pharma	543,736,000
Rate used to discount net cash inflows to present values	11.00%						12.50%
Percentage of fair value of IPR&D represented by three research projects	60.00%
Expected cost to complete the three projects										10,000,000
Identified intangible assets	186,000,000	130,000,000
Acquisition costs expensed			12,700,000		12,700,000
Business acquisition pro forma amortization of fair value of inventory costs					12,000,000
Business acquisition pro forma amortization of intangibles			24,600,000	24,600,000
Percentage of ownership in less than wholly owned subsidiary						71.20%
Purchase of an additional portion of the remaining interest from minority shareholders for cash			5,000,000	182,200,000
Company's total ownership and control in less than wholly owned subsidiary		98.00%	97.00%	96.00%
Research and Development Expense		294,728,000	282,146,000	275,258,000				18,000,000
Intangible assets acquired through contingent consideration		376,100,000
Percentage interest in joint venture sold				50.00%
Percentage interest in joint venture purchased				50.00%
Percentage of stake previously held by subsidiary in joint venture				50.00%
Net cash outflow for other transactions				$ 5,300,000